Find clinical trials

A continuation study for patients rolling over from TAK-079-3002 or TAK-079-1004 with the purpose of evaluating the long-term efficacy of mezagitamab in participants ?18 years of age with chronic primary ITP. The trial is structured to include periods of safety follow up, long term observation and on-demand dosing.

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems.

The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks).

During the study, participants will visit their study clinic several times.

This trial aims to evaluate the safety and efficacy of zasocitinib vs. Placebo in adults with Hidradenitis Suppurativa (HS). The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times.